buy sell hold 2021

UOB KAYHIAN CGS CIMB
Aoxin Q & M Dental Group (AOXIN SP)
Potential Unlocking Of Huge Value Via Nasdaq Listing Of Associated Company

Aoxin’s 49% associated company, Acumen, is exploring a listing on Nasdaq. Our basecase estimate using 22x 2021F PE for Acumen, based on Q&M Dental’s historical mean PE, will unlock value of S$216m (S$0.42/share) for Aoxin. Compared to current market cap of Aoxin at S$127m (S$0.25/share), shareholders will enjoy more than 70% upside in value accretion upon successful of listing, with continued ownership of the China dental business. Maintain BUY and target price of S$0.37 (16x 2022F PE).
Read More ...

Keppel Corporation
4Q21F: Generous dividend


■ We expect KEP to report c.53% hoh increase in net profit in 2H21F (on 27 Jan) to S$459m, boosted by divestment gains of c.S$396m.
■ KEP clocked in S$1.6bn of proceeds in 2H21F from asset recycling efforts, paving way for stronger final DPS of S$0.16-0.18 (FY21F: S$0.28-S$0.30)
■ Reiterate Add with higher SOP TP of S$7.20 as we roll over to FY23F.
■ KEP trades at 0.85x and 11x CY22F P/BV and P/E, -1 sd below its historical
average. Catalyst: aggressive asset recycling and earnings accretive M&As. 

 

Read More ...

MAYBANK KIM ENG

UOB KAYHIAN

Axis REIT (AXRB MK)
Higher acquisition targets


Maintain as top BUY

4QFY21 core earnings and 4th interim gross DPU of 2.41sen (FY21: 9.49sen) were within expectations, with FY21 earnings coming in at 96%/100% of our/consensus estimates. We adjust higher our FY22/23E earnings by 1%/12%, which increases our rolled-forward DDM-TP to MYR2.30. Maintain BUY. Axis remains as our top pick in the REITs sector, supported by resilient rental income from industrial properties and active assets acquisitions.

 

Read More ...

 

 

 

 

Sentral REIT (SENTRAL MK)
4Q21: Results Within Expectations


Sentral REIT’s results came in within our estimates, with full-year 2021 core earnings
accounting for 98% of our full-year forecast. Operations remain fairly resilient and we
believe SENTRAL will continue to report decent results moving forward, given that its
tenants are mostly well-established MNCs. The stock offers an attractive dividend yield
of at least 8% from 2022 onwards. Maintain BUY and target price of RM1.00. 

 

Read More ...